Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company develops unique molecular delivery systems. Its spherical micrometer sizes polymer particles act like micro sponges and absorb molecules while the sub-micrometer sized Hollow silica shells have an internal void space and act much like a standard container.
Fluxion develops cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Bionanotechnology and microfluidics provide the foundations for GeneFluidics' testing platform. The use of bionanotechnology drives high signal to noise ratios (sensitivity), while the incorporation of microfluidics permits operational simplicity.
Genetix is an independent business unit within Leica Microsystems. The company provides scientists and clinicians with unrivalled solutions for imaging and intelligent image analysis in the life science and clinical markets.
Genovis has a broad knowledge within physics, biology and biochemistry and offers nanoparticles as tools in medical imaging and for in vitro/in vivo transfections. We have developed a new category of nanoparticles that generate a contrast effect in more than one type of medical imaging technique and offer customer made nanoparticles which besides the particles per se also include method development and services in the form of pre-studies that are specifically adapted to the individual needs of the customer.
Genovoxx is developing a technology for the massively parallel sequencing by synthesis of nucleic acids. This technology enables the sequencing of many millions of nucleic acids molecules in parallel format at the single molecule level.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
(German language site) The company is a Contract Research Organisation for the development and improvement of advanced cell culture systems for industrial drug screening applications, biomaterial testing and pharma-toxicological research.
A spin off founded to commercialize FDEC FET nano sensor technology invented at Arizona State University.The novel nano sensor technology is capable of exponential capacitive transduction for ultra high sensitivity molecular detection, coupled with exceptional selectivity.
Inanovate creates nano-scale surface structures through a unique and proprietary process capable of nano-meter precision in a time and cost effective way. Leveraging this unique platform and expertise, Inanovate is developing nano-structured biochip substrates to facilitate the next generation in biochip technology.